Compare Intuitive Surgical, Inc. (ISRG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Novartis AG — how do they compare? Intuitive Surgical, Inc. trades at $398.8 (market cap $141.75B), while Novartis AG trades at $153.11 (market cap $295.37B). The key difference: Novartis AG is far larger — about 2.1× Intuitive Surgical, Inc.'s market cap, and Novartis AG pays a 3.07% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| ISRG | NVS | |
|---|---|---|
Market Cap | $141.75B | $295.37B |
Sector | Health | Health |
52-Week High | $592.85 | $168.62 |
52-Week Low | $332.02 | $119.31 |
Enterprise Value | $136.53B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $393.38, up 3.85% on the day, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The stock exhibits premium valuation metrics, including a P/E of 46.01 and P/S of 13.08, supported by robust revenue growth, which reached $10.06B in 2025, and high net income margins of 28.45%. Recent news highlights analyst upgrades and optimism around the da Vinci 5 system's adoption.
The outlook remains positive given durable demand and innovation, but risks include heightened competition and valuation sensitivity. Wall Street consensus is bullish with a $518.10 price target, implying significant upside, though investors should weigh premium multiples against growth sustainability and competitive pressures in the medtech space.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
